People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study
Introduction This patient preference study sought to quantify the preferences of people living with COPD regarding symptom improvement in the UK, USA, France, Australia and Japan. Methods The inclusion criteria were people living with COPD aged 40 years or older who experienced ≥1 exacerbation in th...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2022-06-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/8/2/00686-2021.full |
| _version_ | 1797809456904404992 |
|---|---|
| author | Nigel S. Cook Gerard J. Criner Pierre-Régis Burgel Katie Mycock Tom Gardner Phil Mellor Pam Hallworth Kate Sully Sophi Tatlock Beyza Klein Byron Jones Olivier Le Rouzic Kip Adams Kirsten Phillips Mike McKevitt Kazuko Toyama Florian S. Gutzwiller |
| author_facet | Nigel S. Cook Gerard J. Criner Pierre-Régis Burgel Katie Mycock Tom Gardner Phil Mellor Pam Hallworth Kate Sully Sophi Tatlock Beyza Klein Byron Jones Olivier Le Rouzic Kip Adams Kirsten Phillips Mike McKevitt Kazuko Toyama Florian S. Gutzwiller |
| author_sort | Nigel S. Cook |
| collection | DOAJ |
| description | Introduction
This patient preference study sought to quantify the preferences of people living with COPD regarding symptom improvement in the UK, USA, France, Australia and Japan.
Methods
The inclusion criteria were people living with COPD aged 40 years or older who experienced ≥1 exacerbation in the previous year with daily symptoms of cough and excess mucus production. The study design included: 1) development of an attributes and levels grid through qualitative patient interviews; and 2) implementation of the main online quantitative survey, which included a discrete choice experiment (DCE) to allow assessment of attributes and levels using hypothetical health state profiles. Preference weights (utilities) were derived from the DCE using hierarchical Bayesian analysis. A preference simulator was developed that enabled different health state scenarios to be evaluated based on the predicted patient preferences.
Results
1050 people living with moderate-to-severe COPD completed the survey. All attributes were considered important when patients determined their preferences in the DCE. In a health state preference simulation, two hypothetical health states (comprising attribute levels) with qualitatively equivalent improvements in A) cough and mucus and B) shortness of breath (SOB) resulted in a clear preference for cough and mucus improved profile. When comparing two profiles with C) daily symptoms improved and D) exacerbations improved, there was a clear preference for the daily symptoms improved profile.
Conclusions
People living with moderate-to-severe COPD prefer to reduce cough and mucus production together over improvement of SOB and would prefer to reduce combined daily symptoms over an improvement in exacerbations. |
| first_indexed | 2024-03-13T06:53:05Z |
| format | Article |
| id | doaj.art-c0f0fb8255bd40bebc8809974a271e87 |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-03-13T06:53:05Z |
| publishDate | 2022-06-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-c0f0fb8255bd40bebc8809974a271e872023-06-07T13:30:09ZengEuropean Respiratory SocietyERJ Open Research2312-05412022-06-018210.1183/23120541.00686-202100686-2021People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference studyNigel S. Cook0Gerard J. Criner1Pierre-Régis Burgel2Katie Mycock3Tom Gardner4Phil Mellor5Pam Hallworth6Kate Sully7Sophi Tatlock8Beyza Klein9Byron Jones10Olivier Le Rouzic11Kip Adams12Kirsten Phillips13Mike McKevitt14Kazuko Toyama15Florian S. Gutzwiller16 Novartis Pharma AG, Basel, Switzerland Temple University, Philadelphia, PA, USA Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France Adelphi Real World, Macclesfield, UK Adelphi Research, Macclesfield, UK Adelphi Research, Macclesfield, UK Adelphi Research, Macclesfield, UK Adelphi Values, Macclesfield, UK Adelphi Values, Macclesfield, UK Novartis Pharma AG, Basel, Switzerland Novartis Pharma AG, Basel, Switzerland La Fondation du Souffle, Paris, France COPD Foundation, Miami, FL, USA Lung Foundation Australia, Brisbane, Australia British Lung Foundation, London, UK J-Breath, Tokyo, Japan Novartis Pharma AG, Basel, Switzerland Introduction This patient preference study sought to quantify the preferences of people living with COPD regarding symptom improvement in the UK, USA, France, Australia and Japan. Methods The inclusion criteria were people living with COPD aged 40 years or older who experienced ≥1 exacerbation in the previous year with daily symptoms of cough and excess mucus production. The study design included: 1) development of an attributes and levels grid through qualitative patient interviews; and 2) implementation of the main online quantitative survey, which included a discrete choice experiment (DCE) to allow assessment of attributes and levels using hypothetical health state profiles. Preference weights (utilities) were derived from the DCE using hierarchical Bayesian analysis. A preference simulator was developed that enabled different health state scenarios to be evaluated based on the predicted patient preferences. Results 1050 people living with moderate-to-severe COPD completed the survey. All attributes were considered important when patients determined their preferences in the DCE. In a health state preference simulation, two hypothetical health states (comprising attribute levels) with qualitatively equivalent improvements in A) cough and mucus and B) shortness of breath (SOB) resulted in a clear preference for cough and mucus improved profile. When comparing two profiles with C) daily symptoms improved and D) exacerbations improved, there was a clear preference for the daily symptoms improved profile. Conclusions People living with moderate-to-severe COPD prefer to reduce cough and mucus production together over improvement of SOB and would prefer to reduce combined daily symptoms over an improvement in exacerbations.http://openres.ersjournals.com/content/8/2/00686-2021.full |
| spellingShingle | Nigel S. Cook Gerard J. Criner Pierre-Régis Burgel Katie Mycock Tom Gardner Phil Mellor Pam Hallworth Kate Sully Sophi Tatlock Beyza Klein Byron Jones Olivier Le Rouzic Kip Adams Kirsten Phillips Mike McKevitt Kazuko Toyama Florian S. Gutzwiller People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study ERJ Open Research |
| title | People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study |
| title_full | People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study |
| title_fullStr | People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study |
| title_full_unstemmed | People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study |
| title_short | People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study |
| title_sort | people living with moderate to severe copd prefer improvement of daily symptoms over the improvement of exacerbations a multicountry patient preference study |
| url | http://openres.ersjournals.com/content/8/2/00686-2021.full |
| work_keys_str_mv | AT nigelscook peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT gerardjcriner peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT pierreregisburgel peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT katiemycock peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT tomgardner peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT philmellor peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT pamhallworth peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT katesully peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT sophitatlock peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT beyzaklein peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT byronjones peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT olivierlerouzic peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT kipadams peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT kirstenphillips peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT mikemckevitt peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT kazukotoyama peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy AT floriansgutzwiller peoplelivingwithmoderatetoseverecopdpreferimprovementofdailysymptomsovertheimprovementofexacerbationsamulticountrypatientpreferencestudy |